You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Accession NumberDB09026  (DB01258)
GroupsApproved, Investigational
DescriptionNot Available
Protein structureNo structure small 354e4808da70a5bd16896d40d8e7c4c304b2c46d0efa4be7aa608033bb036952
Protein chemical formulaNot Available
Protein average weightNot Available
SynonymsNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Rasileztablet150 mgoralNovartis Pharmaceuticals Canada IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rasileztablet300 mgoralNovartis Pharmaceuticals Canada IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
CategoriesNot Available
CAS numberNot Available
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ManufacturersNot Available
PackagersNot Available
Dosage forms
Tabletoral150 mg
Tabletoral300 mg
PricesNot Available
PatentsNot Available
Experimental PropertiesNot Available
Synthesis ReferenceNot Available
General ReferenceNot Available
External Links
ATC CodesC09XA02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Drug Interactions
AlfuzosinMonitor therapy due to enhanced hypotensive effect of aliskiren.
AmifostineAmifostine hypotensive effect can be exacerbated with administration of antihypertensives. If amifostine is administered, no antihypertensives should be administered within 24 hours. If the antihypertensives can't be withheld, amifostine should not be administered.
AtorvastatinTherapy modification should be considered because atorvastatin increases aliskiren serum concentration.
BrimonidineMonitor therapy because of enhanced hypotensive effect.
CanagliflozinMonitor therapy because canagliflozin may enhance aliskiren antihypertensive and hyperkalemic effects.
CyclosporineAvoid combination because cyclosporine increases aliskiren serum concentration.
DiazoxideMonitor therapy due to enhanced hypotensive effect of aliskiren.
DuloxetineMonitor therapy due to enhanced orthostatic hypotensive effect of duloxetine.
FurosemideMonitor therapy due to potential decreased serum concentration of furosemide.
HeparinMonitor therapy due to enhanced hyperkalemic effect of aliskiren.
ItraconazoleAvoid combination due to increased serum concentration of aliskiren.
KetoconazoleMonitor therapy due to increased serum concentration of aliskiren.
MethylphenidateMonitor therapy due to reduced antihypertensive effect of aliskiren.
ObinutuzumabObinutuzumab antihypertensive effect may be enhanced. Administration of antihypertensives should be withheld 12 hours before infusion of obinutuzumab and 1 hour after the end of infusion.
PentoxifyllineMonitor therapy due to enhanced antihypertensive effects of aliskiren.
RituximabConsider therapy modification due to enhanced hypotensive effect of rituximab.
VerapamilMonitor therapy due to increased concentration of aliskiren.
YohimbineMonitor therapy due to decreased antihypertensive effects of aliskiren.
Food InteractionsNot Available
comments powered by Disqus
Drug created on October 13, 2014 16:29 / Updated on October 13, 2014 16:29